RxDoctor Payments Data

Joel Solano, MD

Ophthalmology · Palm Desert, CANPI 1952380834

Payments from drug & device makers

$9,491in general payments, 2019–2025

Across 11 payments — averaging $862.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Thea Pharma Inc.$9K
  • Rxsight Inc$155
  • Ivantis, Inc$32
  • AbbVie$24
  • Sight Sciences, Inc.$18
  • Amgen$15
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$6,40768%
  • Travel & lodging$2,82830%
  • Food & beverage$2563%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,491 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$633,742
Medicare patients
1,240
Services billed
4,719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Latanoprost3,800$60,314
RhopressaNetarsudil Mesylate78$44,258
Cyclosporine43$26,926
LumiganBimatoprost60$24,131
Timolol Maleate1,603$22,056
RestasisCyclosporine32$20,000
SimbrinzaBrinzolamide/Brimonidine Tart44$11,188
VyzultaLatanoprostene Bunod19$10,787
Dorzolamide Hcl475$9,100
Brimonidine Tartrate485$7,997
CombiganBrimonidine Tartrate/Timolol28$7,477
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat296$7,165
Brinzolamide28$6,493
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$3,986
Travoprost20$3,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$24$51,608120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Palm Desert

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →